Newland Pharmaceutical Co., Ltd. (SHE:301277)

Newland Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	123.89	169	281.58	270.02	51.13	34.21
Trading Asset Securities	542.35	549.55	525.16	589.5	701.36	8.67
Cash & Short-Term Investments	666.23	718.55	806.75	859.52	752.49	42.88
Cash Growth	-15.40%	-10.93%	-6.14%	14.22%	1654.94%	17.63%
Accounts Receivable	368.82	270.55	332.61	240.9	360.46	269.6
Other Receivables	0.19	0.03	0.06	0.19	0.26	0.16
Receivables	369.01	270.58	332.67	241.09	360.72	269.76
Inventory	66.35	72.37	45.06	31	53.52	78.57
Other Current Assets	4.21	5.18	10.55	25.04	20.38	9.8
Total Current Assets	1,106	1,067	1,195	1,157	1,187	401
Property, Plant & Equipment	648.08	659.65	574.78	388.2	295.52	225.67
Other Intangible Assets	49.52	49.99	36.82	38.08	38.77	39.71
Long-Term Deferred Tax Assets	-	-	-	-	-	1.01
Long-Term Deferred Charges	0.92	1.34	3.38	5.61	1.29	-
Other Long-Term Assets	18.29	1.85	3.73	20.96	11.08	0.51
Total Assets	1,823	1,780	1,814	1,610	1,534	667.9

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	105.51	97.68	138.66	87.75	106.37	80.26
Accrued Expenses	14.89	24.37	23.78	30.33	18.18	27.81
Short-Term Debt	0.47	-	0.73	-	-	91.33
Current Portion of Long-Term Debt	-	-	-	-	-	4.66
Current Portion of Leases	2.07	2.81	-	1.99	2.84	-
Current Income Taxes Payable	8.29	0.06	-	-	-	3.05
Current Unearned Revenue	4.47	3.28	5.32	4.43	4.61	1.68
Other Current Liabilities	38.41	42.17	48.3	14.96	24.01	11.8
Total Current Liabilities	174.11	170.35	216.78	139.47	156.01	220.58
Long-Term Debt	-	-	-	-	-	30.39
Long-Term Leases	1.39	2.89	2.25	0.73	2.88	-
Long-Term Unearned Revenue	50.13	44.23	41.88	10.04	10.3	10.56
Long-Term Deferred Tax Liabilities	10.5	11.02	9.77	9.78	5.39	-
Total Liabilities	236.14	228.49	270.69	160.02	174.58	261.53

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	392.08	392.08	280.06	200.04	133.36	100
Additional Paid-In Capital	532.74	532.74	644.77	724.78	791.46	5.49
Retained Earnings	656.03	619.93	610.7	517.09	424.79	292.48
Comprehensive Income & Other	6.28	6.59	6.67	6.11	6.33	4.56
Total Common Equity	1,587	1,551	1,542	1,448	1,356	402.53
Minority Interest	-0.65	-0.33	0.85	1.47	3.25	3.85
Shareholders' Equity	1,586	1,551	1,543	1,449	1,359	406.38
Total Liabilities & Equity	1,823	1,780	1,814	1,610	1,534	667.9

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	3.94	5.69	2.98	2.72	5.72	126.38
Net Cash (Debt)	662.3	712.86	803.77	856.8	746.77	-83.5
Net Cash Growth	-15.37%	-11.31%	-6.19%	14.73%	-	-
Net Cash Per Share	1.69	1.82	2.04	2.19	2.48	-0.28
Filing Date Shares Outstanding	392.08	392.08	392.08	392.08	392.08	294
Total Common Shares Outstanding	392.08	392.08	392.08	392.08	392.08	294
Working Capital	931.71	896.33	978.24	1,017	1,031	180.43
Book Value Per Share	4.05	3.96	3.93	3.69	3.46	1.37
Tangible Book Value	1,538	1,501	1,505	1,410	1,317	362.82
Tangible Book Value Per Share	3.92	3.83	3.84	3.60	3.36	1.23
Buildings	-	380.5	211.94	169.21	151.69	148.36
Machinery	-	467.7	295.69	235.66	187.31	125.82
Construction In Progress	-	13.46	222.1	106.7	55.35	33.02

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 27, 2026

Data Sources Report a data error